Welcome to our dedicated page for Lilly Eli & news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & stock.
Eli Lilly & Co. develops and commercializes medicines across cardiometabolic disease, oncology, immunology, neuroscience and genetic medicine. Company news commonly covers product and pipeline developments for medicines such as Mounjaro, Zepbound, Foundayo, Omvoh, Verzenio, Jaypirca and Taltz, including clinical data, regulatory approvals and treatment-indication updates.
Lilly updates also include operating results, financial guidance, dividends, business development agreements and manufacturing expansion. Recent company communications highlight investment in active pharmaceutical ingredient capacity and genetic medicine production, alongside recurring disclosures about demand for diabetes, obesity, immune-disease and cancer therapies.
Eli Lilly and Company (NYSE: LLY) released findings from the CONFIDE Study, revealing that bowel urgency is the second most reported symptom among individuals with moderately-to-severely active ulcerative colitis (UC), affecting 47% in the past month. Notably, only 38.2% of those experiencing bowel urgency felt comfortable discussing it with healthcare providers, highlighting a significant communication gap. Despite 76.5% of respondents receiving advanced therapies, bowel urgency persisted in 46.4% of cases. The study emphasizes the need for improved patient-provider communication regarding this disruptive symptom.
The FDA has expanded the Emergency Use Authorization (EUA) for bamlanivimab and etesevimab for high-risk pediatric patients under 12 years. This allows treatment of mild to moderate COVID-19 and post-exposure prophylaxis. The decision was supported by findings from the BLAZE-1 clinical trial, showing a median symptom resolution time of 5 to 7 days. Over 700,000 patients have been treated, potentially preventing over 35,000 hospitalizations. No deaths or hospitalizations were recorded among pediatric subjects during the trial.
Eli Lilly and Company (NYSE: LLY) will hold an investment community meeting on Dec. 15, 2021, from 9 a.m. to 4 p.m. Eastern time. The meeting will include the company's initial financial guidance for 2022 and an in-depth discussion on its research and development opportunities in diabetes, immunology, neuroscience, and oncology. The event will be accessible via a live video webcast, with a replay available after the meeting.
Eli Lilly and Company (NYSE: LLY) has opened enrollment for the CHALLENGE-MIG clinical trial, the first head-to-head comparison of the anti-CGRP drugs Emgality® (galcanezumab-gnlm) and Nurtec® ODT (rimegepant) for episodic migraine prevention in adults. The trial will assess the efficacy of monthly Emgality injections against bi-daily Nurtec tablets, focusing on migraine days reduction and quality of life. Approximately 700 adults will participate, with results anticipated to guide treatment decisions. The study highlights Lilly's commitment to advancing migraine treatment options.
Eli Lilly and Company (NYSE: LLY) will participate in the fourth annual Evercore ISI HealthCONx Conference on Nov. 30, 2021. Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific and medical officer, will engage in a fireside chat at 12:10 p.m. Eastern time. A live audio webcast of the event will be available on Lilly's Investor website, with a replay accessible for 90 days post-event.
Lilly, a global healthcare leader, focuses on creating impactful medicines and enhancing disease management.
The FDA has accepted a supplemental New Drug Application for Jardiance (empagliflozin) 10 mg, granting it Priority Review. This application aims to establish Jardiance as a treatment for reducing the risk of cardiovascular death and hospitalization for heart failure in adults, regardless of left ventricular ejection fraction (LVEF). In the EMPEROR-Preserved trial, Jardiance showed a 21% relative risk reduction for the primary endpoint versus placebo. If approved, it would be the first treatment proven to improve outcomes in patients with preserved ejection fraction heart failure.
Eli Lilly and Company (NYSE: LLY) has announced the winners of the inaugural Leonard Award, celebrating the 100th anniversary of insulin's discovery. Each of the five awardees will receive $20,000, totaling $100,000 in donations to Life for a Child, which aids children with type 1 diabetes in low-resource settings. The winners were chosen from over 70 submissions evaluated by an esteemed panel based on impact and feasibility. This initiative highlights Lilly's ongoing commitment to diabetes care and community support.
Eli Lilly and Company (NYSE: LLY) will participate in the Wolfe Research Virtual Healthcare Conference on Nov. 18, 2021. Key executives, including Jacob Van Naarden, CEO of Loxo Oncology, will engage in a fireside chat at 10:30 a.m. Eastern time. Investors can access the event via a live audio webcast on the company's investor website, with a replay available for 90 days afterward. Lilly is committed to improving global health through innovative medicines and community support, continuing a century-old mission.
OLUMIANT (baricitinib) continues to demonstrate a consistent safety profile in a long-term analysis involving 3,770 rheumatoid arthritis (RA) patients across 14,744 patient years of exposure. The overall incidence rate of adverse events stood at 22.6 per 100 patient years, with serious adverse events at 7.4. Safety results will be presented by Eli Lilly and Company and Incyte at ACR Convergence 2021. A real-world study in Japan involving 3,445 RA patients also showed no new safety signals, reinforcing OLUMIANT's safety over 24 weeks. OLUMIANT is approved in over 75 countries for RA treatment.
The EMPEROR-Preserved phase III trial revealed that Jardiance (empagliflozin) significantly reduces the risk of cardiovascular death or hospitalization for heart failure and slows kidney function decline in adults with heart failure and left ventricular ejection fraction (LVEF) over 40%. Presented at the American Society of Nephrology Kidney Week 2021, findings showed consistent benefits regardless of chronic kidney disease (CKD) status. The trial included nearly 6,000 adults, with results highlighting the potential for Jardiance as a viable treatment option. Fast Track and Breakthrough Therapy designations have been granted for its cardiovascular applications.